The potential benefits to in vivo PI3K therapy prior to leukapheresis or T-cell isolation may have direct impacts on having a more favorable baseline T-cell phenotype for CART or increased T-cell yield from tumor for TIL therapy. This evidence concerns the gene PIK3CB and neoplasm.